Mistletoe-Based Drugs Work in Synergy with Radio-Chemotherapy in the Treatment of Glioma In Vitro and In Vivo in Glioblastoma Bearing Mice
Figure 3
Drug-induced modulation of proliferation and cell cycle distribution in glioma cells. (a) Growth curve of ML-treated LNT-229 glioma cells. Cells were treated for 24 h with ISCADOR Qu (ISC Qu), Aviscumine (Avi) (0, 2.4, 4.8, or 8 ng/ml), or native ML-1 (0, 4.8, 8, or 16 ng/ml). After treatment the medium was changed to drug-free growth medium and cell growth was measured by crystal violet staining every 24 h (FC, fold change). (b) Cell cycle distribution of treated LNT-229 glioma cells 48 h after treatment. The cells were treated with ISC Qu, Avi, or native ML-1 at increasing concentrations in the presence of absence of a ML-specific antibody (4.8 µg/ml). (c) RT-qPCR analysis of LNT-229 cells treated for 24 h with 8 ng/ml ISCADOR Qu (I), Aviscumine (A), or native ML-1 (M). The dashed line demonstrates baseline expression in untreated control cells (GOI gene of interest; FC fold change; n=3; ±SD; Student’s t-test P < 0.05, P < 0.01, and P < 0.001).